Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS/NRAS Mutation”

46 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 46 results

Early research (Phase 1)Study completedNCT02729298
What this trial is testing

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal Carcinoma+2 more
Sumitomo Pharma America, Inc. 177
Not applicableStudy completedNCT02827565
What this trial is testing

Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Institut de Cancérologie de Lorraine 30
Early research (Phase 1)Looking for participantsNCT06096974
What this trial is testing

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

Who this might be right for
Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd. 60
Not applicableLooking for participantsNCT04151342
What this trial is testing

CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Who this might be right for
CancerMalignancies MultipleMalignant Solid Tumor+7 more
University Health Network, Toronto 5,500
Testing effectiveness (Phase 2)Study completedNCT01704703
What this trial is testing

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

Who this might be right for
Stage IV Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 72
Testing effectiveness (Phase 2)Study completedNCT05039177
What this trial is testing

ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Who this might be right for
Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma
Erasca, Inc. 101
Early research (Phase 1)Study completedNCT04853017
What this trial is testing

ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Who this might be right for
Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more
Elicio Therapeutics 25
Not applicableAvailableNCT04566393
What this trial is testing

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

Who this might be right for
Pancreatic CancerSmall Bowel CancerColorectal Cancer+18 more
xCures
Large-scale testing (Phase 3)Looking for participantsNCT07252232
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Early research (Phase 1)Looking for participantsNCT07252479
What this trial is testing

Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations

Who this might be right for
Solid Tumors (Phase 1)RAS Mutation
Adlai Nortye Biopharma Co., Ltd. 91
Testing effectiveness (Phase 2)Looking for participantsNCT07397338
What this trial is testing

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Solid TumorsNon-small Cell Lung Cancer (NSCLC)+3 more
Revolution Medicines, Inc. 370
Large-scale testing (Phase 3)Study completedNCT02394795
What this trial is testing

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

Who this might be right for
Colorectal Cancer
Takeda 823
Testing effectiveness (Phase 2)Study completedNCT03745326
What this trial is testing

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Who this might be right for
Gastrointestinal CancerPancreatic CancerGastric Cancer+2 more
National Cancer Institute (NCI) 5
Early research (Phase 1)Ended earlyNCT04249843
What this trial is testing

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Who this might be right for
Solid TumorB-Raf Mutation-Related Tumors
MapKure, LLC 109
Testing effectiveness (Phase 2)Active Not RecruitingNCT05726864
What this trial is testing

ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Who this might be right for
Pancreatic Ductal AdenocarcinomaColorectal CancerKRAS G12D+11 more
Elicio Therapeutics 158
Early research (Phase 1)Study completedNCT03118817
What this trial is testing

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

Who this might be right for
Solid Tumor
Hanmi Pharmaceutical Company Limited 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT06106308
What this trial is testing

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Who this might be right for
Metastatic Colorectal CancerCRCKRAS/NRAS Mutation
Cardiff Oncology 113
Testing effectiveness (Phase 2)Active Not RecruitingNCT02079740
What this trial is testing

Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
National Cancer Institute (NCI) 96
Testing effectiveness (Phase 2)UnknownNCT03457896
What this trial is testing

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Who this might be right for
Metastatic Colorectal Cancer
NSABP Foundation Inc 35
Load More Results